Publication details
Technological development of bioequivalent omeprazole product
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases of the upper gastrointestinal tract due to their highly selective inhibitory effect on the acid-forming function of the stomach. The primary drug from the PPI group is omeprazole, which was synthesized in 1979 after discovering a unique enzyme, K+-stimulated ATPase, in parietal cells during experiments on the gastric mucosa [1]. In 2023, omeprazole was found to be the third most commonly prescribed chemical substance in England, with the drug listed on approximately 35 million prescriptions [2]. The localization of pharmaceutical drug production is one of Europe's primary strategies to ensure that the population has access to affordable and good-quality medicines. This study describes the technological development of bioequivalent delayed-release omeprazole. |